文献速递骨质疏松与钙磷/甲状旁腺

特立帕肽对绝经前特发性骨质疏松骨重建与密度的影响:II期试验

Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该II期随机对照试验纳入41例绝经前特发性骨质疏松女性,比较特立帕肽20 mcg与安慰剂6个月对腰椎aBMD、骨转换标志物及骨形成率的影响。结果显示特立帕肽组腰椎aBMD增加5.5%,显著高于安慰剂组的1.5%(P=0.007),并持续改善24个月aBMD。

要点

  • 特立帕肽6个月显著提高腰椎aBMD(5.5% vs 1.5%,P=0.007)。
  • 特立帕肽增加3个月骨转换标志物及骨形成率(P=0.004)。
  • 24个月特立帕肽持续增加腰椎、全髋和股骨颈aBMD。

核心结论

  • 特立帕肽增加骨形成率及形成标志物,并与大多数(82%)绝经前特发性骨质疏松女性aBMD显著改善相关。

研究设计与样本

  • 6个月II期随机对照试验(特立帕肽20 mcg n=28,安慰剂 n=13),随后开放扩展至24个月。
  • 对象为绝经前特发性骨质疏松女性,共41例随机。

主要发现

  • 6个月腰椎aBMD变化:特立帕肽组5.5%(95%CI 3.83,7.19),安慰剂组1.5%(95%CI -0.73,3.83),组间P=0.007。
  • 3个月骨形成率(松质骨和内皮骨)组间P=0.004。
  • 24个月特立帕肽组腰椎aBMD增加13.2%(95%CI 10.3,16.2),全髋增加5.2%(95%CI 3.7,6.7),股骨颈增加5.0%(95%CI 3.2,6.7),均P≤0.001。
  • 血清P1NP和3个月内皮骨骨形成率与腰椎aBMD反应中度相关。

临床怎么用

  • 特立帕肽可用于绝经前特发性骨质疏松女性,以增加骨形成和aBMD。
  • 治疗期间可监测P1NP和骨形成率以预测腰椎aBMD反应。

局限性

  • 样本量较小(41例),为II期试验。
  • 开放扩展部分无对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Premenopausal women with idiopathic osteoporosis (IOP) have abnormal skeletal microarchitecture and variable tissue-level bone formation rate (BFR). OBJECTIVES: Compare 6 months (M) of teriparatide versus placebo on areal bone mineral density (aBMD) by dual-energy x-ray absorptiometry (DXA), bone turnover markers (BTMs) and BFR at 3M by quadruple-labeled transiliac biopsy. Characterize 12M and 24M effects of teriparatide on aBMD and whether BTMs and BFR predict response. DESIGN: 6M phase 2 randomized controlled trial (RCT) followed by open extension. SETTING: Tertiary referral centers. PATIENTS: Premenopausal women with IOP. INTERVENTIONS: A total of 41 women were randomized to either teriparatide 20 mcg (n = 28) or placebo (n = 13). After 6M, those on placebo switched to teriparatide for 24M; those on teriparatide continued for 18M. MAIN OUTCOME MEASURES: 6M RCT: Between-group differences in lumbar spine (LS) aBMD (percent change from baseline), 3M BFR, and hypercalcemia. Open-label extension: Within-group change in LS aBMD over 12M and 24M. Secondary outcomes included aBMD change at other sites and relationship between BTMs, BFR, and changes in aBMD. FINDINGS: Over 6M, LS aBMD increased by 5.5% (95% CI: 3.83, 7.19) in teriparatide and 1.5% (95% CI: -0.73, 3.83) in placebo (P = 0.007). There were increases in 3M BTMs, and BFR (cancellous and endocortical BFR: between-groups P = 0.004). Over 24M, teriparatide increased LS aBMD by 13.2% (95% CI: 10.3, 16.2), total hip by 5.2% (95% CI: 3.7, 6.7) and femoral neck by 5.0% (95% CI: 3.2, 6.7; all P ≤ 0.001). Serum N-terminal propeptides of procollagen type 1 (P1NP) and 3M endocortical BFR were moderately associated with LS aBMD response. Teriparatide was well-tolerated. CONCLUSIONS: Teriparatide increased BFR and formation markers and was associated with marked aBMD improvements in most premenopausal women (82%) with IOP.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Cohen A, Shiau S, Nair N, et al. Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial. J Clin Endocrinol Metab. 2020. PMID: 32876328. doi:10.1210/clinem/dgaa489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。